Holen Sie sich die Stockscreener-App
1.02
0.97%
-0.01
Vorhandelsmarkt:
1.00
-0.02
-1.96%
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - marketscreener.com
RenovoRx Inc Presents Clinical Data Supporting Targeted Chemotherapeutic Delivery Via Tamp Therapy Platform - marketscreener.com
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - The Manila Times
Pancreatic cancer scans show early response after artery-delivered chemo - Stock Titan
Fund Flows: Is RenovoRx Inc exposed to political risk2026 Trading Volume Trends & Real-Time Sentiment Analysis - baoquankhu1.vn
Meme Stocks: Is RenovoRx Inc a defensive stockWeekly Trade Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - ADVFN
Signal Recap: Whats the outlook for RenovoRx Incs sector2026 Sector Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
RenovoRx (RNXT) price target increased by 18.52% to 8.16 - MSN
RenovoRx receives Japanese patent for RenovoCath device By Investing.com - Investing.com Australia
RNXT: HC Wainwright Reiterates Buy Rating and $3.00 Price Target - GuruFocus
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Bitget
RenovoRx receives Japanese patent for RenovoCath device - Investing.com
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Investing News Network
Cancer drug-delivery device wins Japan patent allowance as RenovoRx expands - Stock Titan
RenovoRx (NASDAQ: RNXT) CEO receives 946,107 stock options grant - Stock Titan
RenovoRx (RNXT) CMO granted 621,727 options vesting through 2030 - Stock Titan
Stock Recap: How does RenovoRx Inc perform in inflationary periods2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
RenovoRx, Inc. Appoints Ramtin Agah, M.D. As Executive Chairman , Effective February 27, 2026 - marketscreener.com
RNXT Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Taiwan News
Street Watch: How does RenovoRx Inc perform in inflationary periods2026 Price Action Summary & Reliable Price Breakout Signals - baoquankhu1.vn
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - 富途牛牛
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial - The Globe and Mail
RNXT SEC FilingsRenovorx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RenovoRx Reports Solid First Full Year of RenovoCath Commercialization - National Today
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Trade Recap: What chart patterns are forming on RenovoRx IncMarket Performance Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Published on: 2026-03-31 14:32:17 - baoquankhu1.vn
RNXT: 2026 revenue is projected to triple as commercial site expansion accelerates and funding strengthens - TradingView
Earnings call transcript: RenovoRx Q4 2025 results show revenue growth By Investing.com - Investing.com South Africa
RNXT: 2025 revenue reached $1.1M, with 2026 guidance of $3–$4M and rapid commercial site expansion - TradingView
Earnings call transcript: RenovoRx Q4 2025 results show revenue growth - Investing.com
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update - Investing News Network
RNXT: 2025 revenue rose to $1.1M, but net loss increased as commercialization and R&D spending grew - TradingView — Track All Markets
RenovoRx (NASDAQ: RNXT) surges 2025 revenue and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx (NASDAQ: RNXT) grows RenovoCath use and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
RNXT: 2025 revenue reached $1.1M as RenovoCath adoption expanded; TIGER-PAC trial nears completion - TradingView — Track All Markets
RenovoRx, Inc. (RNXT) Q4 FY2025 earnings call transcript - Yahoo Finance
RenovoRx 2025 net loss widens on higher operating expenses - TradingView — Track All Markets
BRIEF-RenovoRx FY Net Income USD -11.168 Million - TradingView
Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 Result - gurufocus.com
RenovoRx Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) CFO granted 12,380 RSUs, now reports 134,580 shares - Stock Titan
RenovoRx (RNXT) CFO discloses 25,000 shares bought pre-role - Stock Titan
RenovoRx appoints Dr. Ramtin Agah as executive chairman and updates compensation - Investing.com
[8-K] RenovoRx, Inc. Reports Material Event - stocktitan.net
RenovoRx surpasses 100 patients in Phase III pancreatic trial By Investing.com - Investing.com South Africa
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment - Investing News Network
Sell Signal: Is RenovoRx Inc stock a value trapInsider Selling & Smart Swing Trading Alerts - baoquankhu1.vn
RenovoRx surpasses 100 patients in Phase III pancreatic trial - Investing.com
RenovoRx pancreatic cancer trial passes 100 patients, 2027 data next - Stock Titan
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):